In cooperation with the Disease Prevention and Control Center (SPKC) and State Council of Immunization, ZVA concluded that currently there are neither scientific nor epidemiological grounds to restrict vaccination with the “Vaxzevria” vaccine produced by AstraZeneca in any age groups. The experts recommend that all population groups continue to be vaccinated with this vaccine.
The ZVA noted that the responsible authorities have taken such a decision by assessing the final report of the European Medicines Agency (EMA) on very rare cases of blood clots with a reduction in thrombocyte count after receiving the vaccine. The State Council for Immunization said that there was no cause for concern about the increase in the risk of very rare unusual blood clots following the second dose of the vaccine, because there have been no reports of these very rare cases of unusual blood clots in the European Economic Area as well as Britain following a second dose of vaccine.
It is highly recommended that people who have received the first dose of AstraZeneca vaccine, also get the second dose, as this is important for the development of persistent immunity against Covid-19, ZVA said.